Доступ, удовлетворенность, соблюдение и безопасность к подкожному натенению по сравнению с внутривенным внутриутробным склерозом в реальной группе населения: первый доклад Латинской Америки.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Silva Berenice A, Santajuliana Franco, Casas Magdalena, Lázaro Luciana, Pita Cecilia, Cohen Leila, Rinaldi Guido, Alonso Ricardo, Míguez Jimena, D'Alessandro Sofía
Аннотация
Оригинал публикации
Access, satisfaction, adherence and safety to subcutaneous natalizumab compared to intravenous natalizumab in multiple sclerosis in a real-life cohort: first report from Latin America.
BACKGROUND: Subcutaneous natalizumab (scN) was recently approved in Argentina for people with multiple sclerosis (pwMS). The impact of this change in this population is unknown.
OBJECTIVES: To evaluate the use, access and satisfaction of scN and correlate it with clinical and demographic variables. Desing: cross-sectional study was conducted, surveying pwMS who received scN and ivN from public and private MS Centres since its approval.
METHODS: Treatment adherence was assessed using the MS Treatment Adherence Questionnaire (MS-TAQ) and satisfaction using Treatment Satisfaction of Questionnaire for Medication (TSQM). Clinical and demographic variables were also recorded. Results: 84 pwMS were included, 58.3% female, mean EDSS: 2.4 ± 1.2, mean age: 34.8 ± 10.8 years, mean disease duration: 7.8 ± 4.5 years, mean time under N: 43.7 ± 28.7 months, 45.2% naïve of prior disease modifying treatments, 77.4% (n = 65) under scN (60.7%, n = 51 are switchers from ivN, 49% due to difficult access to an infusion centre); and 22.6% 8 (n = 19) under ivN. The main barrier for change from iv to sc was the refusal from health insurance. Of the total of pwMS, 42% (n = 36) had a delay or lack of at least one dose from their social insurance, all from public hospitals. We found an association between scN use and high scores on the convenience items of TSQM (p < 0.0001, X 2 = 74), unlike ivN. Regardless of route of administration, most of pwMS showed high percentages of satisfaction in the effectiveness and global satisfaction items, without differences between ivN and scM.
CONCLUSION: We found a high rate of change to scN from ivN, associated with a higher score in the comfort and convenience items in people receiving scN, compared to ivN. Access barriers should be addressed in order to improve treatment comfort.